These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 8931636

  • 1. The enteroinsular axis in dipeptidyl peptidase IV-negative rats.
    Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CH.
    Metabolism; 1996 Nov; 45(11):1335-41. PubMed ID: 8931636
    [Abstract] [Full Text] [Related]

  • 2. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
    Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB.
    Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
    [Abstract] [Full Text] [Related]

  • 3. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion.
    Jia X, Brown JC, Ma P, Pederson RA, McIntosh CH.
    Am J Physiol; 1995 Apr; 268(4 Pt 1):E645-51. PubMed ID: 7733263
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B, Hughes TE.
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [Abstract] [Full Text] [Related]

  • 5. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ, McIntosh CH, Pederson RA.
    Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
    [Abstract] [Full Text] [Related]

  • 6. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
    Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K.
    Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R, Gallwitz B, Schmidt WE.
    Eur J Biochem; 1993 Jun 15; 214(3):829-35. PubMed ID: 8100523
    [Abstract] [Full Text] [Related]

  • 8. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC, Göke R, Göke B, Bächle R, Wagner B, Arnold R.
    Biochim Biophys Acta; 1991 Feb 19; 1091(3):356-63. PubMed ID: 1705823
    [Abstract] [Full Text] [Related]

  • 9. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide.
    Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA.
    Metabolism; 1999 Mar 19; 48(3):385-9. PubMed ID: 10094118
    [Abstract] [Full Text] [Related]

  • 10. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
    Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA.
    Diabetes; 2003 Mar 19; 52(3):741-50. PubMed ID: 12606516
    [Abstract] [Full Text] [Related]

  • 11. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr 19; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 12. Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.
    Jia X, Elliott R, Kwok YN, Pederson RA, McIntosh CH.
    Diabetes; 1995 May 19; 44(5):495-500. PubMed ID: 7729605
    [Abstract] [Full Text] [Related]

  • 13. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.
    J Endocrinol; 2006 Oct 19; 191(1):93-100. PubMed ID: 17065392
    [Abstract] [Full Text] [Related]

  • 14. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
    Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP.
    Arch Biochem Biophys; 2004 Aug 15; 428(2):136-43. PubMed ID: 15246869
    [Abstract] [Full Text] [Related]

  • 15. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.
    Diabetologia; 2003 Feb 15; 46(2):222-30. PubMed ID: 12627321
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Sakagami H, Kitsunai H, Takiyama Y, Abiko A, Makino Y, Kieffer TJ, Haneda M.
    Mol Metab; 2017 Feb 15; 6(2):226-231. PubMed ID: 28180064
    [Abstract] [Full Text] [Related]

  • 17. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
    Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, Seino Y, McIntosh CH, Pederson RA.
    Am J Physiol Endocrinol Metab; 2003 May 15; 284(5):E931-9. PubMed ID: 12540373
    [Abstract] [Full Text] [Related]

  • 18. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X, Harada N, Yamane S, Kitajima L, Uchida S, Hamasaki A, Mukai E, Toyoda K, Yamada C, Yamada Y, Seino Y, Inagaki N.
    Life Sci; 2009 Jun 19; 84(25-26):876-81. PubMed ID: 19358859
    [Abstract] [Full Text] [Related]

  • 19. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK.
    Regul Pept; 1994 Apr 14; 51(1):63-74. PubMed ID: 8036284
    [Abstract] [Full Text] [Related]

  • 20. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ.
    J Endocrinol; 2002 Feb 14; 172(2):355-62. PubMed ID: 11834453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.